Securian Asset Management Inc. Sells 7,219 Shares of Stryker Corporation $SYK

Securian Asset Management Inc. reduced its holdings in Stryker Corporation (NYSE:SYK) by 43.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 9,359 shares of the medical technology company’s stock after selling 7,219 shares during the period. Securian Asset Management Inc.’s holdings in Stryker were worth $3,289,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in SYK. Corient Private Wealth LLC increased its position in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after buying an additional 1,146,998 shares during the period. Alliancebernstein L.P. increased its position in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares during the period. Strive Asset Management LLC bought a new position in Stryker in the 3rd quarter worth approximately $227,389,000. Credit Agricole S A bought a new position in Stryker in the 3rd quarter worth approximately $194,045,000. Finally, Pictet Asset Management Holding SA increased its position in Stryker by 190.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 466,256 shares of the medical technology company’s stock worth $163,878,000 after buying an additional 305,640 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

SYK opened at $285.49 on Monday. The stock’s 50 day simple moving average is $340.37 and its 200-day simple moving average is $355.17. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a market cap of $109.34 billion, a PE ratio of 33.04, a P/E/G ratio of 1.80 and a beta of 0.80. Stryker Corporation has a 1 year low of $284.95 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s payout ratio is currently 40.74%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SYK. Citigroup lowered their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. William Blair restated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Needham & Company LLC lowered their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Evercore set a $355.00 price objective on Stryker in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. lowered their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.